Cited by 1,460Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase SignalingProtein Tyrosine Phosphatases

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Open access

Johannessen, Cory M., Boehm, Jesse S., Kim, So Young, Thomas, Sapana R., Wardwell, Leslie, Johnson, Laura A., Emery, Caroline M., Stransky, Nicolas, Cogdill, Alexandria P., Barretina, Jordi, Caponigro, Giordano, Hieronymus, Haley, Murray, Ryan R., Salehi-Ashtiani, Kourosh, Hill, David E., Vidal, Marc, Zhao, Jean J., Yang, Xiaoping, Alkan, Ozan, Kim, Sungjoon, Harris, Jennifer L., Wilson, Christopher J., Myer, Vic E., Finan, Peter M., Root, David E., Roberts, Thomas M., Golub, Todd, Flaherty, Keith T., Dummer, Reinhard, Weber, Barbara L., Sellers, William R., Schlegel, Robert, Wargo, Jennifer A., Hahn, William C., Garraway, Levi A.·2010·Nature

DOI 10.1038/nature09627PMC PMC3058384

Open this paper in CoChat — free account

Abstract

Oncogenic mutations in the serine/threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas. Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma-an observation that has been validated by the success of RAF and MEK inhibitors in clinical trials. However, clinical responses to targeted anticancer therapeutics are frequently confounded by de novo or acquired resistance. Identification of resistance mechanisms in a manner that elucidates alternative 'druggable' targets may inform effective long-term treatment strategies. Here we expressed ∼600 kinase and kinase-related open reading frames (ORFs) in parallel to interrogate resistance to a selective RAF kinase inhibitor. We identified MAP3K8 (the gene encoding COT/Tpl2) as a MAPK pathway agonist that drives resistance to RAF inhibition in B-RAF(V600E) cell lines. COT activates ERK primarily through MEK-dependent mechanisms that do not require RAF signalling. Moreover, COT expression is associated with de novo resistance in B-RAF(V600E) cultured cell lines and acquired resistance in melanoma cells and tissue obtained from relapsing patients following treatment with MEK or RAF inhibitors. We further identify combinatorial MAPK pathway inhibition or targeting of COT kinase activity as possible therapeutic strategies for reducing MAPK pathway activation in this setting. Together, these results provide new insights into resistance mechanisms involving the MAPK pathway and articulate an integrative approach through which high-throughput functional screens may inform the development of novel therapeutic strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nature09627

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Self-citation
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citation
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citation
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citation
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P., Garnett, M. J., Roe, S. M., Lee, S., Niculescu‐Duvaz, D., Good, V. M., Cancer Genome Project, Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,863
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G. E., Shokat, K. M., & Rosen, N. X. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,841
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Hatzivassiliou, G., Song, K. W., Yen, I., Brandhuber, B. J., Anderson, D. J., Alvarado, R., Ludlam, M. J. C., Stokoe, D., Gloor, S. L., Vigers, G. P. A., et al. (2010) · Nature · doi:10.1038/nature08833 · Cited by 1,649
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Heidorn, S. J., Milagre, C. S., Whittaker, S. R., Nourry, A., Niculescu‐Duvaz, I., Dhomen, N. S., Hussain, J., Reis-Filho, J. S., Springer, C. J., Pritchard, C. A., et al. (2010) · Cell · doi:10.1016/j.cell.2009.12.040 · Cited by 1,497

Flagged first, then by citations

Show all 30 references

Sorted by citations

Items 901–1,000 of 1,002

Novel Therapies in Melanoma
Scheier, B. Y., Amaria, R. N., Lewis, K. D., & Gonzalez, R. C. (2011) · Immunotherapy · doi:10.2217/imt.11.136 · Cited by 17
Effect of MAP3K8 on Prognosis and Tumor-Related Inflammation in Renal Clear Cell Carcinoma
Hao, J., Cao, Y., Yu, H., Zong, L., An, R., & Xue, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.674613 · Cited by 17
ARAF suppresses ERBB3 expression and metastasis in a subset of lung cancers
Mooz, J., Riegel, K., Hari, P. S., Sadanandam, A., Marini, F., Klein, M., Werner, U., Roth, W., Wilken‐Schmitz, A., Tegeder, I., et al. (2022) · Science Advances · doi:10.1126/sciadv.abk1538 · Cited by 17
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma
Rudloff, U. (2022) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2022.2134346 · Cited by 17
RAF and MEK Inhibitors in Non-Small Cell Lung Cancer
Adamopoulos, C., Papavassiliou, K. A., Poulikakos, P. I., & Papavassiliou, A. G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094633 · Cited by 18
BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip1
Jang, G., & Lee, M. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.02.036 · Cited by 17
Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma
Pérez‐Lorenzo, R., & Zheng, B. (2011) · Bioscience Reports · doi:10.1042/bsr20110068 · Cited by 17
Principles of Kinase Inhibitor Therapy for Solid Tumors
Cohen, N. A., Kim, T. S., & DeMatteo, R. P. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001740 · Cited by 18
MiR-511 mimic transfection inhibits the proliferation, invasion of osteosarcoma cells and reduces metastatic osteosarcoma tumor burden in nude mice via targeting MAPK1
Wu, J., Zhang, C., & Chen, L. (2019) · Cancer Biomarkers · doi:10.3233/cbm-190534 · Cited by 18
Targeting effector pathways in RAC1 P29S -driven malignant melanoma
Uribe‐Alvarez, C., Guerrero-Rodríguez, S., Rhodes, J., Cannon, A. C., Chernoff, J., & Araiza‐Olivera, D. (2020) · Small GTPases · doi:10.1080/21541248.2020.1728469 · Cited by 17
Vertical Pathway Targeting in Cancer Therapy
Shahbazian, D., Sznol, J. A., & Kluger, H. M. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00001-4 · Cited by 17
Combination therapy of BRAF inhibitors for advanced melanoma with BRAF V600 mutation: a systematic review and meta-analysis
Kim, S., Kim, H. T., & Suh, H. S. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1330530 · Cited by 17
Self-citation
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function
Manzini, C., Venè, R., Cossu, I., Gualco, M., Zupo, S., Dono, M., Spagnolo, F., Queirolo, P., Moretta, L., Mingari, M. C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11504 · Cited by 16
Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors
Ahlborn, L. B., Tuxen, I. V., Mouliere, F. C., Kinalis, S., Schmidt, A. Y., Rohrberg, K. S., Santoni‐Rugiu, E., Nielsen, F. C., Lassen, U., Yde, C. W., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25948 · Cited by 16
BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma
Gebhardt, K., Edemir, B., Groß, E., Nemetschke, L., Kewitz, S., Moritz, R. K. C., Sunderkötter, C. H., & Gerloff, D. (2021) · Cancers · doi:10.3390/cancers13102393 · Cited by 16
CRISPR-based kinome-screening revealed MINK1 as a druggable player to rewire 5FU-resistance in OSCC through AKT/MDM2/p53 axis
Mohanty, S., Mohapatra, P., Shriwas, O., Ansari, S. A., Priyadarshini, M., Priyadarsini, S., Rath, R., Sultania, M., Majumdar, S. K. D., Swain, R. K., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02475-8 · Cited by 16
Detecting Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma
Lo, R. S., & Shi, H. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-727-3_10 · Cited by 17
YL529 , a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models
Xu, Y., Lin, H., Meng, N., Lu, W., Li, G., Han, Y., Dai, X., Xia, Y., Song, X., Yang, S., et al. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12216 · Cited by 16
Screens, maps & networks: from genome sequences to personalized medicine
Sandmann, T., & Boutros, M. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.02.001 · Cited by 17
Drug Design of Cyclin-Dependent Kinase 2 Inhibitor for Melanoma from Traditional Chinese Medicine
Tang, H., & Chen, C. Y. (2014) · BioMed Research International · doi:10.1155/2014/798742 · Cited by 15
Developing melanoma therapeutics: overview and update
Korman, J. B., & Fisher, D. E. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1210 · Cited by 16
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Caparica, R., de Castro, G., Bazo, I. G., Caglevic, C., Calogero, R., Giallombardo, M., Santos, E. S., Raez, L. E., & Rolfo, C. D. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.02.012 · Cited by 16
Next-Generation Sequencing to Guide Treatment of Advanced Melanoma
Griewank, K., & Schilling, B. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0260-6 · Cited by 17
Choroidal Neovascularization in Multifocal Choroiditis after Dabrafenib and Trametinib
Albertini, G. C., Corbelli, E., Parodi, M. B., & Bandello, F. M. (2017) · European Journal of Ophthalmology · doi:10.5301/ejo.5001013 · Cited by 16
Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization
Bolan, P. O., Zviran, A., Brenan, L., Schiffman, J. S., Dusaj, N. N., Goodale, A. B., Piccioni, F., Johannessen, C. M., & Landau, D. A. (2019) · Cell Systems · doi:10.1016/j.cels.2019.10.002 · Cited by 15
Self-citation
Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine
Warthaka, M., Adelmann, C. H., Kaoud, T. S., Edupuganti, R., Yan, C., Johnson, W. H., Ferguson, S. B., Tavares, C. D. J., Pence, L. J., Anslyn, E. V., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500198b · Cited by 15
Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma
Coventry, B. J., Lilly, C. A., Hersey, P., Michele, A., & Bright, R. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-9 · Cited by 15
Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance
Choi, P. S., Li, Y., & Felsher, D. W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406123111 · Cited by 16
Dual c-JunN-terminal kinase-cyclin D1 and extracellular signal-related kinase-c-Jun disjunction in human melanoma
Pathria, G., Garg, B., Garg, K., Wagner, C., & Wagner, S. N. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14713 · Cited by 17
Integrating Transcriptomic Data with Mechanistic Systems Pharmacology Models for Virtual Drug Combination Trials
Barrette, A. M., Bouhaddou, M., & Birtwistle, M. R. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00197 · Cited by 17
Mechanisms Regulating the Association of Protein Phosphatase 1 with Spinophilin and Neurabin
Edler, M., Salek, A. B., Watkins, D. S., Kaur, H., Morris, C. W., Yamamoto, B. K., & Baucum, A. J. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00144 · Cited by 16
Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells.
Basile, K. J., & Aplin, A. E. (2012) · PubMed Central · Cited by 16
Pathological activation of CaMKII induces arrhythmogenicity through TRPM4 overactivation
Hu, Y., Ross‐Kaschitza, D., Essers, M. C., Arullampalam, P., Fujita, T., Abriel, H., & Inoue, R. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02507-w · Cited by 15
Recent advances in cutaneous melanoma: towards a molecular model and targeted treatment
Read, J. (2013) · Australasian Journal of Dermatology · doi:10.1111/ajd.12013 · Cited by 15
Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma
Ades, F., & Metzger, O. (2011) · Dermatology Research and Practice · doi:10.1155/2012/259170 · Cited by 15
Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsets
Flaherty, K. T. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9488-y · Cited by 15
Self-citation
Impact of MET expression on outcome in BRAF V600E/K advanced melanoma
Jubb, A. M., Ribas, A., Sosman, J. A., McArthur, G. A., Yan, Y., Rost, S., Zhao, S. S., & Koeppen, H. (2013) · Histopathology · doi:10.1111/his.12169 · Cited by 15
New Therapeutic Targets in Melanoma
Martí, R. M., Sorolla, A., & Yeramian, A. (2012) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2012.08.005 · Cited by 15
Molecular alterations in signal pathways of melanoma and new personalized treatment strategies: Targeting of Notch
Mozūraitienė, J., Bielskienė, K., Atkočius, V., & Labeikytė, D. (2015) · Medicina · doi:10.1016/j.medici.2015.06.002 · Cited by 15
Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations
Lehmann, B. D., Shaver, T. M., Johnson, D. B., Li, Z., Ericsson, P. I. G., Sanchez, V. M., Shyr, Y., Sanders, M. E., & Pietenpol, J. A. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0257 · Cited by 15
Mammalian Sterile 20-Like Kinase (MST) 1/2: Crucial Players in Nervous and Immune System and Neurological Disorders
Qi, Y., Sun, D., Yang, W., Xu, B., Lv, D., Han, Y., Sun, M., Jiang, S., Hu, W., & Yang, Y. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2020.03.010 · Cited by 15
miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma
Nguyen, M.-H., Lin, C.-H., Liu, S., Miyashita, A., Ihn, H., Lin, H., Ng, C., Tsai, J.-C., Chen, M., Tsai, M.-S., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.10.009 · Cited by 17
Downregulation of SOX2 by inhibition of Usp9X induces apoptosis in melanoma
Potu, H., Kandarpa, M., Peterson, L. F., Durham, A. B., Donato, N. J., & Talpaz, M. (2021) · Oncotarget · doi:10.18632/oncotarget.27869 · Cited by 15
Resistance to Targeted Therapy and RASSF1A Loss in Melanoma: What Are We Missing?
McKenna, S., & García-Gutiérrez, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105115 · Cited by 15
Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells
Misek, S. A., Newbury, P. A., Chekalin, E., Paithankar, S., Doseff, A. I., Chen, B., Gallo, K. A., & Neubig, R. R. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.121.000331 · Cited by 14
EGFR transactivates RON to drive oncogenic crosstalk
Nitta, C. F., Green, E. W., Jhamba, E. D., Keth, J. M., Ortiz-Caraveo, I., Grattan, R. M., Schodt, D. J., Gibson, A. C., Rajput, A., Lidke, K. A., et al. (2021) · eLife · doi:10.7554/elife.63678 · Cited by 15
Targeted Therapy for Brain Metastases
Davies, M. A. (2012) · Advances in pharmacology · doi:10.1016/b978-0-12-397927-8.00005-1 · Cited by 16
Cucurbitacin B, Purified and Characterized From the Rhizome of Corallocarpus epigaeus Exhibits Anti-Melanoma Potential
Aiswarya, S. U. D., Vikas, G., Haritha, N. H., Liju, V. B., Shabna, A., Swetha, M., Rayginia, T. P., Keerthana, C. K., Nath, L. R., Reshma, M. V., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903832 · Cited by 17
Acquired resistance to molecularly targeted therapies for cancer
Stubbs, N. M., Roady, T. J., Schwermann, M. P., Eteshola, E. O. U., MacDonald, W., Purcell, C., Ryspayeva, D., Verovkina, N., Tajiknia, V., Ghandali, M., et al. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2024.189 · Cited by 18
Effective inhibition of melanoma by BI‐69A11 is mediated by dual targeting of the AKT and NF‐κB pathways
Feng, Y., Barile, E., De, S. K., Stebbins, J. L., Cortez, A., Aza‐Blanc, P., Villanueva, J., Heryln, M., Krajewski, S., Pellecchia, M., et al. (2011) · Pigment Cell & Melanoma Research · doi:10.1111/j.1755-148x.2011.00867.x · Cited by 14
Combination Molecularly Targeted Drug Therapy in Metastatic Melanoma: Progress to Date
Lemech, C., Infante, J. R., & Arkenau, H. (2013) · Drugs · doi:10.1007/s40265-013-0049-8 · Cited by 14
Group I p21-activated kinases facilitate Tax-mediated transcriptional activation of the human T-cell leukemia virus type 1 long terminal repeats
Chan, C.-P., Siu, Y., Kok, K., Ching, Y.-P., Tang, H.-M. V., & Jin, D. (2013) · Retrovirology · doi:10.1186/1742-4690-10-47 · Cited by 14
Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?
Catalanotti, F., & Solit, D. B. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0626 · Cited by 14
Vemurafenib
Keating, G. M. (2012) · BioDrugs · doi:10.2165/11209860-000000000-00000 · Cited by 14
Biomarkers in Melanoma: Lessons from Translational Medicine
Buchbinder, E. I., & Flaherty, K. T. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.003 · Cited by 14
Self-citation
Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma
Paulitschke, V., Eichhoff, O. M., Cheng, P. F., Levesque, M. P., & Höeller, C. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000261 · Cited by 11
ErbB4 tyrosine kinase inhibition impairs neuromuscular development in zebrafish embryos
Paatero, I., Veikkolainen, V., Mäenpää, M., Schmelzer, E., Belting, H., Pelliniemi, L. J., & Elenius, K. (2018) · Molecular Biology of the Cell · doi:10.1091/mbc.e18-07-0460 · Cited by 15
MAGI1 inhibits the AMOTL2/p38 stress pathway and prevents luminal breast tumorigenesis
Kantar, D., Bousquet, E., Mancini, M., Slaninová, V., Salah, Y. B., Costa, L., Forest, E., Lassus, P., Géminard, C., Boissière‐Michot, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85056-1 · Cited by 13
Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis
Cherepakhin, O. S., Argényi, Z. B., & Moshiri, A. S. (2021) · Cancers · doi:10.3390/cancers14010123 · Cited by 15
Physical and functional interaction of the TPL2 kinase with nucleophosmin
Kanellis, D. C., Bursać, S., Tsichlis, P. N., Volarević, S., & Eliopoulos, A. G. (2014) · Oncogene · doi:10.1038/onc.2014.183 · Cited by 14
A Methodological Approach to Unravel Organ-Specific Breast Cancer Metastasis
Nola, S., Sin, S., Bonin, F., Lidereau, R., & Driouch, K. (2012) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-012-9256-2 · Cited by 14
Suppression of B-Raf(V600E) cancers by MAPK hyper-activation
Atiq, R., Hertz, R., Eldad, S., Smeir, E., & Bar‐Tana, J. (2016) · Oncotarget · doi:10.18632/oncotarget.7909 · Cited by 14
Proteolytic cleavages in the extracellular domain of receptor tyrosine kinases by membrane-associated serine proteases
Chen, L., & Chai, K. X. (2017) · Oncotarget · doi:10.18632/oncotarget.17009 · Cited by 14
Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death
Xu, X., Eshima, S., Kato, S., Fisher, D. E., Sakurai, H., Hayakawa, Y., & Yokoyama, S. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0451 · Cited by 16
MAP 3K8 kinase regulates myeloma growth by cell‐autonomous and non‐autonomous mechanisms involving myeloma‐associated monocytes/macrophages
Hebron, E., Hope, C. L., Kim, J., Jensen, J. L., Flanagan, C. E., Bhatia, N., Maroulakou, I. G., Mitsiades, C. S., Miyamoto, S., Callander, N. S., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12175 · Cited by 14
The role of EGFR monoclonal antibodies (MoABs) cetuximab/panitumab, and BRAF inhibitors in BRAF mutated colorectal cancer.
Muhammad, S., Jiang, Z., Liu, Z., Kaur, K., & Wang, X. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2078-6891.2012.044 · Cited by 13
Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis
Shabna, A., Antony, J., Vijayakurup, V., Saikia, M., Liju, V. B., Retnakumari, A. P., Amrutha Nisthul, A., Alex, V. V., Swetha, M., Aiswarya, S. U. D., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04476-y · Cited by 13
CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy
Zhang, P., Feng, X., Niu, X., Liu, Z., Li, M., Liu, M., Yan, D., Zhang, G., & Wan, X. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00618-7 · Cited by 13
TGF ‐β1 and TNF ‐α differentially regulate T wist1 mediated resistance towards BRAF / MEK inhibition in melanoma
Menon, D. R., Wels, C., Rad, E. B., Joshi, S., Knausz, H., Lade‐Keller, J., Brandner, J. M., & Schaider, H. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12139 · Cited by 14
The GIST of Targeted Therapy for Malignant Melanoma
Bello, D. M., DeMatteo, R. P., & Ariyan, C. E. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3373-z · Cited by 13
Overcoming metastatic melanoma with BRAF inhibitors
Hong, S., & Hong, S. (2011) · Archives of Pharmacal Research · doi:10.1007/s12272-011-0521-5 · Cited by 13
New RAF kinase inhibitors in cancer therapy
Martín-Liberal, J., & Larkin, J. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.911286 · Cited by 14
Targeted Therapy in Melanoma
Glitza, I. C., Kim, D. W., Chae, Y. K., & Kim, K. B. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3554-3_11 · Cited by 13
Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma
Schulz, A., Raetz, J., Karitzky, P. C., Dinter, L., Tietze, J. K., Kolbe, I., Käubler, T., Renner, B., Beissert, S., Meier, F. E., et al. (2022) · Cancers · doi:10.3390/cancers14194930 · Cited by 15
Reading between the lines; understanding drug response in the post genomic era
Alifrangis, C., & McDermott, U. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.05.014 · Cited by 13
Towards Personalized Therapy for Patients with Malignant Melanoma: Molecular Insights into the Biology of BRAF Mutations
Bradish, J. R., Montironi, R., Antonio Lopez-beltran, B., Post, K. M., MacLennan, G. T., & Liang Cheng, C. (2013) · Future Oncology · doi:10.2217/fon.12.179 · Cited by 16
Melanoma therapy: Check the checkpoints
Furue, M., & Kadono, T. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13257 · Cited by 13
PLX4032 and melanoma: resistance, expectations and uncertainty
Roukos, D. H. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.3 · Cited by 13
The safety and efficacy of cobimetinib for the treatment of BRAF V600E or V600K melanoma
Amaral, T. M. S., Nouri, N., & Garbe, C. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1192469 · Cited by 13
Genetic deletion of sphingosine kinase 1 suppresses mouse breast tumor development in an HER2 transgenic model
Shimizu, Y., Furuya, H., Tamashiro, P. M., Iino, K., Chan, O. T. M., Steve Goodison, B., Pagano, I., Hokutan, K., Peres, R., Loo, L. W. M., et al. (2017) · Carcinogenesis · doi:10.1093/carcin/bgx097 · Cited by 13
Spinophilin regulates phosphorylation and interactions of the GluN2B subunit of the N‐methyl‐ d ‐aspartate receptor
Salek, A. B., Edler, M., McBride, J. P., & Baucum, A. J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14831 · Cited by 13
Upregulation of S100A9 contributes to the acquired resistance to BRAF inhibitors
Hwang, S., Ahn, J., & Lee, M. (2019) · Genes & Genomics · doi:10.1007/s13258-019-00856-0 · Cited by 13
Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells
Ahn, J.-H., Han, B., & Lee, M. (2015) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2015.007 · Cited by 13
Structural Basis of Analog Specificity in PKG I and II
Campbell, J. C., Henning, P., Franz, E., Sankaran, B., Herberg, F. W., & Kim, C. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00369 · Cited by 13
Inhibition of retinoic acid receptor β signaling confers glycolytic dependence and sensitization to dichloroacetate in melanoma cells
Abildgaard, C., Dahl, C., Abdul-Al, A., Christensen, A., & Guldberg, P. (2017) · Oncotarget · doi:10.18632/oncotarget.20476 · Cited by 13
Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts
Nishida‐Aoki, N., Zhu, S., Chan, M., Kang, Y., Fujita, M., Jiang, X., McCabe, M. C., Vaz, J. M., Davidson, N. E., Ghajar, C. M., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102357 · Cited by 11
Anti-tumoral effect of beta-blockers on prostate and bladder cancer cells via mitogen-activated protein kinase pathways
Özler, S., & Pazarcı, P. (2022) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001271 · Cited by 12
Splice variants of CK1α and CK1α-like: Comparative analysis of subcellular localization, kinase activity, and function in the Wnt signaling pathway
Gybeľ, T., Čada, Š., Klementová, D., Schwalm, M. P., Berger, B., Šebesta, M., Knapp, S., & Bryja, V. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107407 · Cited by 13
Landscape of targeted therapies for lung squamous cell carcinoma
Chen, Q., Zheng, X.-S., Cheng, W., & Li, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1467898 · Cited by 15
Targeted Therapies for Cutaneous Melanoma
Kee, D., & McArthur, G. A. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.02.003 · Cited by 12
Molecular Targeted Approaches for AdvancedBRAFV600,N-RAS,c-KIT, andGNAQMelanomas
Ponti, G., Pellacani, G., Tomasi, A., Loschi, P., Luppi, G., Gelsomino, F., & Longo, C. (2014) · Disease Markers · doi:10.1155/2014/671283 · Cited by 12
Treatment of Vemurafenib-Resistant SKMEL-28 Melanoma Cells with Paclitaxel
Nguyen, D. T., Phan, T. N., Kumasaka, M. Y., Yajima, I., & Kato, M. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.2.699 · Cited by 12
What is new in the treatment of advanced melanoma? State of the art
Mackiewicz, J. (2012) · Współczesna Onkologia · doi:10.5114/wo.2012.31763 · Cited by 12
Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis
Krisp, C., Parker, R., Pascovici, D., Hayward, N. K., Wilmott, J. S., Thompson, J. F., Mann, G. J., Long, G. V., Scolyer, R. A., & Molloy, M. P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0227-2 · Cited by 11
Structural basis for antigen recognition by methylated lysine–specific antibodies
Ishii, M., Nakakido, M., Caaveiro, J. M. M., Kuroda, D., Okumura, C. J., Maruyama, T., Entzminger, K. C., & Tsumoto, K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.015996 · Cited by 12
Synthetic Heterodimers of Type III Interferon Receptors Require TYK2 for STAT Activation
Mesev, E. V., Guare, E. G., Ploß, A., & Toettcher, J. E. (2023) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2023.0039 · Cited by 12
Trametinib in metastatic melanoma
Chopra, N., & Nathan, P. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1060127 · Cited by 13
Nuevas dianas terapéuticas en el melanoma
Martí, R. M., Sorolla, A., & Yeramian, A. (2012) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2011.08.009 · Cited by 12
Microsatellite instability status affects gene expression profiles in early onset colorectal cancer patients
Aksoy, S. A., Tunca, B., Yılmazlar, T., Tezcan, G., Çeçener, G., Egelí, Ü., Öztürk, E., Yerci, Ö., Ertürk, E., & Zorluoğlu, A. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.07.014 · Cited by 12
Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma
Capaldo, B. J., Roller, D. G., Axelrod, M. J., Koeppel, A. F., Petricoin, E. F., Slingluff, C. L., Weber, M. J., Mackey, A. J., Gioeli, D. G., & Bekiranov, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138210 · Cited by 12

Authors: Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., Emery, C. M., Stransky, N., Cogdill, A. P., Barretina, J., Caponigro, G., Hieronymus, H., Murray, R. R., Salehi-Ashtiani, K., Hill, D. E., Vidal, M., Zhao, J. J., Yang, X., Alkan, O., Kim, S., Harris, J. L., Wilson, C. J., Myer, V. E., Finan, P. M., Root, D. E., Roberts, T. M., Golub, T., Flaherty, K. T., Dummer, R., Weber, B. L., Sellers, W. R., Schlegel, R., Wargo, J. A., Hahn, W. C., & Garraway, L. A.
Affiliations: Broad Institute (US)
Harvard University (US)
Massachusetts General Hospital (US)
Genomics Institute of the Novartis Research Foundation (US)
Dana-Farber Cancer Institute (US)
University of Zurich (CH)
Corresponding author: Garraway, Levi A.
ORCID: Johannessen, Cory M.
Boehm, Jesse S.
Kim, So Young
Stransky, Nicolas
Cogdill, Alexandria P.
Barretina, Jordi
Hill, David E.
Vidal, Marc
Zhao, Jean J.
Yang, Xiaoping
Alkan, Ozan
Wilson, Christopher J.
Myer, Vic E.
Root, David E.
Roberts, Thomas M.
Golub, Todd
Flaherty, Keith T.
Dummer, Reinhard
Weber, Barbara L.
Sellers, William R.
Wargo, Jennifer A.
Hahn, William C.
Garraway, Levi A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2010-11-24
Volume: 468
Issue: 7326
Pages: 968-972
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature09627
PMC: PMC3058384
OpenAlex: W2141674733
Cited by: 1,460
References: 30
Citations by year: 2026: 19 · 2025: 27 · 2024: 32 · 2023: 55 · 2022: 45 · 2021: 56 · 2020: 67 · 2019: 91 · 2018: 78 · 2017: 102 · 2016: 107 · 2015: 121 · 2014: 158 · 2013: 186 · 2012: 177
FWCI: 65.49
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
Funders: National Institutes of Health (DP2OD002750)
National Cancer Institute (RC2CA148268, R01CA134502, K08CA115927, CA134502, R33CA128625, P50CA093683)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
Keywords: MAP3K8, BRAF inhibitor resistance, vemurafenib, melanoma, BRAF V600E mutation, MAPK signaling
MeSH terms: Vemurafenib, Allosteric Regulation, Clinical Trials as Topic, Enzyme Activation, Humans, Indoles, Melanoma, Proto-Oncogene Proteins, Sulfonamides, Gene Library, Gene Expression Regulation, Neoplastic, Open Reading Frames, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-raf, Gene Expression Profiling, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Kinase Kinases, MAP Kinase Signaling System, Cell Line, Tumor, Protein Kinase Inhibitors, Proto-Oncogene Proteins B-raf

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks